We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

148 hedge funds and large institutions have $582M invested in Intellia Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 29

38% more call options, than puts

Call options by funds: $3.31M | Put options by funds: $2.4M

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

35% more capital invested

Capital invested by funds: $430M → $582M (+$151M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

5% more funds holding

Funds holding: 141 → 148 (+7)

2.59% more ownership

Funds ownership: 72.6% → 75.19% (+2.6%)

Holders
148
Holders Change
+7
Holders Change %
+4.96%
% of All Funds
3.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
26
Increased
49
Reduced
29
Closed
19
Calls
$3.31M
Puts
$2.4M
Net Calls
+$909K
Net Calls Change
+$132K

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$17.6M
2
NAMA
Nikko Asset Management Americas
New York
+$15.9M
3
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$15.6M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$5.41M
5
BlackRock
BlackRock
New York
+$4.67M

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$8.64M
2
State Street
State Street
Massachusetts
-$8M
3
Morgan Stanley
Morgan Stanley
New York
-$3.99M
4
Citigroup
Citigroup
New York
-$3.57M
5
Renaissance Technologies
Renaissance Technologies
New York
-$3.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHK
126
Point72 Hong Kong
Hong Kong
$5K +$2.88K +193 +251%
Nordea Investment Management
127
Nordea Investment Management
Sweden
$5K +$4.47K +300 New
RE
128
RBC Europe
United Kingdom
$4.87K – – –
IA
129
IFP Advisors
Florida
$4K -$14.9K -1,000 -82%
Daiwa Securities Group
130
Daiwa Securities Group
Japan
$4K – – –
TCM
131
Tradewinds Capital Management
Washington
$3K -$1.67K -112 -42%
AA
132
AlphaMark Advisors
Kentucky
$3K – – –
BWP
133
Baldwin Wealth Partners
Massachusetts
$3K – – –
CB
134
CNB Bank
Pennsylvania
$3K – – –
CCM
135
Cribstone Capital Management
Maine
$3K – – –
GWMIA
136
Global Wealth Management Investment Advisory
Florida
$3K – – –
US Bancorp
137
US Bancorp
Minnesota
$3K – – –
FHA
138
Flagship Harbor Advisors
Massachusetts
$2K – – –
LF
139
Lee Financial
Texas
$2K – – –
S
140
SignatureFD
Georgia
$2K +$45 +3 +3%
TRCT
141
Tower Research Capital (TRC)
New York
$2K +$1.79K +120 New
AA
142
Advisory Alpha
Michigan
$1.62K +$1.49K +100 New
PCP
143
Proficio Capital Partners
Massachusetts
$1K +$1.03K +69 New
BCA
144
Berman Capital Advisors
Georgia
$1K +$1.09K +73 New
GT
145
Glenmede Trust
Pennsylvania
$46 – – –
Renaissance Technologies
146
Renaissance Technologies
New York
– -$3.11M -228,000 Closed
Two Sigma Investments
147
Two Sigma Investments
New York
– -$2.02M -148,261 Closed
PP
148
PDT Partners
New York
– -$1.2M -87,743 Closed
GAM
149
Greenwoods Asset Management
Cayman Islands
– -$1.13M -83,031 Closed
First Trust Advisors
150
First Trust Advisors
Illinois
– -$919K -67,322 Closed
3 4 5
6
7

NTLA Hedge Fund Activity: Q1 2019 in Review

148 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2019, worth a combined $582M — up 35% from $430M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NTLA positions and 19 closed out — a net gain of 7 holders — while 49 added to existing stakes and 29 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $17.6M. The largest seller was Deutsche Bank, cutting an estimated $8.64M.

  • 148 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2019, up from 141 in Q4 2018.
  • Funds reported $582M of Intellia Therapeutics stock for Q1 2019, up 35% quarter-over-quarter.
  • 26 funds opened new Intellia Therapeutics positions in Q1 2019 and 19 closed out, a net change of +7 holders.
  • The largest Intellia Therapeutics buyer in Q1 2019 was ARK Investment Management, an estimated $17.6M added.
  • The largest Intellia Therapeutics seller in Q1 2019 was Deutsche Bank, an estimated $8.64M sold.

Based on aggregated 13F filings for Q1 2019.